These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 37605991)

  • 1. DAPA-HF applicability: the point of view of a cardiology setting.
    Iacoviello M; Marini M; Gori M; Orso F; Gonzini L; Gorini M; Fenici P; Maggioni AP
    Acta Cardiol; 2023 Sep; 78(7):840-845. PubMed ID: 37605991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eligibility for Dapagliflozin and Empagliflozin in a Real-world Heart Failure Population.
    Thorvaldsen T; Ferrannini G; Mellbin L; Benson L; Cosentino F; McMurray JJV; Dahlström U; Lund LH; Savarese G
    J Card Fail; 2022 Jul; 28(7):1050-1062. PubMed ID: 35550428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
    Zannad F; Ferreira JP; Pocock SJ; Anker SD; Butler J; Filippatos G; Brueckmann M; Ofstad AP; Pfarr E; Jamal W; Packer M
    Lancet; 2020 Sep; 396(10254):819-829. PubMed ID: 32877652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dapagliflozin in a Real-World Chronic Heart Failure Population: How Many Are Actually Eligible?
    Maltês S; Cunha GJL; Rocha BML; Presume J; Guerreiro R; Henriques C; Rodrigues C; Araújo I; Fonseca C
    Cardiology; 2021; 146(2):201-206. PubMed ID: 33524984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sodium-glucose co-transporter-2 inhibitors eligibility in patients with heart failure with reduced ejection fraction.
    Monzo L; Ferrari I; Cicogna F; Tota C; Calò L
    Int J Cardiol; 2021 Oct; 341():56-59. PubMed ID: 34454968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current Role of Dapagliflozin in Clinical Practice.
    Zargar AH; Trailokya AA; Ghag S; Pawar R; Aiwale A; Zalke A
    J Assoc Physicians India; 2021 Sep; 69(9):11-12. PubMed ID: 34585897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardio-renal benefits of sodium-glucose co-transporter 2 inhibitors in heart failure with reduced ejection fraction: mechanisms and clinical evidence.
    Aguilar-Gallardo JS; Correa A; Contreras JP
    Eur Heart J Cardiovasc Pharmacother; 2022 May; 8(3):311-321. PubMed ID: 34264341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF.
    Docherty KF; Anand IS; Chiang CE; Chopra VK; Desai AS; Kitakaze M; Verma S; Vinh PN; Inzucchi SE; Køber L; Kosiborod MN; Martinez FA; Bengtsson O; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD; Langkilde AM; Jhund PS; McMurray JJV
    JACC Asia; 2022 Apr; 2(2):139-153. PubMed ID: 36339117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sex Differences in Characteristics, Outcomes, and Treatment Response With Dapagliflozin Across the Range of Ejection Fraction in Patients With Heart Failure: Insights From DAPA-HF and DELIVER.
    Wang X; Vaduganathan M; Claggett BL; Hegde SM; Pabon M; Kulac IJ; Vardeny O; O'Meara E; Zieroth S; Katova T; McGrath MM; Pouleur AC; Jhund PS; Desai AS; Inzucchi SE; Kosiborod MN; de Boer RA; Kober L; Sabatine MS; Martinez FA; Ponikowski P; Shah SJ; Hernandez AF; Langkilde AM; McMurray JJV; Solomon SD; Lam CSP
    Circulation; 2023 Feb; 147(8):624-634. PubMed ID: 36342789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SGLT2 inhibitors for heart failure with reduced ejection fraction: a real EMPEROR?
    Raschi E; Fadini GP; Diemberger I; Poluzzi E; De Ponti F
    Expert Opin Pharmacother; 2021 Apr; 22(5):647-650. PubMed ID: 33141609
    [No Abstract]   [Full Text] [Related]  

  • 11. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
    Rao S
    Adv Ther; 2022 Feb; 39(2):845-861. PubMed ID: 34881413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. When and How to Use Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction or Chronic Kidney Disease.
    O'Meara E; Verma S
    Can J Cardiol; 2021 Apr; 37(4):669-673. PubMed ID: 33450364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lessons learned from the DAPA-HF trial concerning the mechanisms of benefit of SGLT2 inhibitors on heart failure events in the context of other large-scale trials nearing completion.
    Packer M
    Cardiovasc Diabetol; 2019 Oct; 18(1):129. PubMed ID: 31585532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF).
    McMurray JJV; DeMets DL; Inzucchi SE; Køber L; Kosiborod MN; Langkilde AM; Martinez FA; Bengtsson O; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD;
    Eur J Heart Fail; 2019 May; 21(5):665-675. PubMed ID: 30895697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of SGLT2 inhibitors on cardiovascular outcomes in patients with heart failure with reduced ejection fraction.
    Starr JA; Pinner NA; Lisenby KM; Osmonson A
    Pharmacotherapy; 2021 Jun; 41(6):526-536. PubMed ID: 33866578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan: The DAPA-HF Trial.
    Solomon SD; Jhund PS; Claggett BL; Dewan P; Køber L; Kosiborod MN; Martinez FA; Ponikowski P; Sabatine MS; Inzucchi SE; Desai AS; Bengtsson O; Lindholm D; Sjostrand M; Langkilde AM; McMurray JJV
    JACC Heart Fail; 2020 Oct; 8(10):811-818. PubMed ID: 32653447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical application of sodium-glucose cotransporter 2 inhibitor into a real-world setting of heart failure care.
    Tanaka A; Node K
    Cardiovasc Diabetol; 2020 Sep; 19(1):132. PubMed ID: 32878601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium/glucose cotransporter 2 inhibitors in chronic kidney disease and heart failure: ready for prime time in patients without diabetes.
    Vlasschaert C; Sidhu B; Silver SA
    Curr Opin Nephrol Hypertens; 2021 May; 30(3):361-368. PubMed ID: 33767064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimated Population Prevalence of Heart Failure with Reduced Ejection Fraction in Spain, According to DAPA-HF Study Criteria.
    Camps-Vilaró A; Delgado-Jiménez JF; Farré N; Tizón-Marcos H; Álvarez-García J; Cinca J; Dégano IR; Marrugat J
    J Clin Med; 2020 Jul; 9(7):. PubMed ID: 32635219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics.
    McMurray JJV; DeMets DL; Inzucchi SE; Køber L; Kosiborod MN; Langkilde AM; Martinez FA; Bengtsson O; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD;
    Eur J Heart Fail; 2019 Nov; 21(11):1402-1411. PubMed ID: 31309699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.